Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Actinium Pharmaceuticals Inc ATNM

Healthcare Biotechnology
Actinium Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing targeted radiotherapies to improve survival for people who have failed existing oncology therapies. The Company’s advanced pipeline candidates include Iomab-B (pre-BLA & MAA (EU)) and Actimab-A. Iomab-B is an induction and conditioning agent prior to bone marrow transplant. Actimab-A... see more

Recent & Breaking News (NYSEAM:ATNM)

Actinium Pharmaceuticals to Host Webinar on June 12th to Update on Pivotal Phase 3 SIERRA Clinical Trial for Iomab-B

GlobeNewswire June 12, 2017

Actinium Pharmaceuticals Announces Appointment of Sandesh Seth as Chief Executive Officer

GlobeNewswire June 9, 2017

Actinium Pharmaceuticals Highlights Presence at Upcoming Society of Nuclear Medicine and Molecular Imaging Annual Meeting

GlobeNewswire June 8, 2017

UPDATE – Actinium Pharmaceuticals to Host Webinar on June 12th to Update on Pivotal Phase 3 SIERRA Clinical Trial for Iomab-B

GlobeNewswire June 8, 2017

Actinium Pharmaceuticals to Host Webinar on June 12th to Update on Pivotal Phase 3 SIERRA Clinical Trial for Iomab-B

GlobeNewswire May 31, 2017

Actinium Pharmaceuticals Granted Orphan Designation from the European Medicines Agency for Actimab-A

GlobeNewswire May 24, 2017

Actinium Pharmaceuticals to Present Actimab-A Data at the 10th International Symposium on Targeted Alpha Therapy

GlobeNewswire May 23, 2017

Research Reports Initiation on Biotech Stocks -- Agenus, Athersys, Actinium Pharma, and AVEO Pharma

PR Newswire May 19, 2017

Actinium Pharmaceuticals Announces Appointment of Hematology Expert Dr. Richard Stone of the Dana-Farber Cancer Institute to its Scientific Advisory Board

GlobeNewswire May 17, 2017

New Cancer Therapeutics Drive the Cancer Biological Therapy Market

PR Newswire February 27, 2017

The Biotech Market Grows as Demand for New Therapeutics Increases

PR Newswire February 6, 2017

Actinium Announces Participation in Three Upcoming Hematology Events

GlobeNewswire January 20, 2017

Actinium Strengthens Executive Team and Enhances Clinical Development Capabilities with the Appointment of Dr. Mark Berger as Chief Medical Officer

GlobeNewswire January 18, 2017

Actinium Pharmaceuticals to Present at 9th Annual Biotech Showcase™ 2017 Conference 

GlobeNewswire January 10, 2017

Actinium Pharmaceuticals to Present at 9th Annual Biotech Showcase™ 2017 Conference

GlobeNewswire January 4, 2017

Actinium Pharmaceuticals Appoints Jeannine Larrieux, Ph.D. as Director of Analytical Development to Support BLA and IND Enabling Analytical Studies for Current and Future Clinical Programs

GlobeNewswire December 19, 2016

Actinium Pharmaceuticals Announces Submission of EU Orphan Designation Application for Actimab-A

GlobeNewswire December 13, 2016

Actinium to Sponsor Upcoming Blood & Marrow Transplant Information Network Webinar Focused on Stem Cell Transplants for Patients with AML

GlobeNewswire December 12, 2016

Actinium Highlights Results from Phase 1 Clinical Trial of Actimab-A at 58th American Society of Hematology Annual Meeting

GlobeNewswire December 5, 2016

Actinium Further Strengthens Clinical Development Team with Senior Hire to Support Later-Stage Clinical Trials

GlobeNewswire November 29, 2016